Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 8/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 6/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 6/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 6/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 6/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 6/20 | 0.41 |
| ▸ | PNP | P00491 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3919290 | 0.81 | TYMS (0.47) | TYMSGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1716189 | 0.78 | TYMS (0.44) | TYMSPNPXDHDHFRALDH1A1 | |
| SCHEMBL9983171 | 0.74 | TYMS (0.38) | TYMSGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4321330 | 0.74 | TYMS (0.42) | TYMSDHFRALDH1A1TDP1 | |
| SCHEMBL9871854 | 0.73 | ALDH1A1 (0.39) | ALDH1A1TDP1 | |
| SCHEMBL5973745 | 0.73 | GRIN2D (0.38) | TYMSGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL13022826 | 0.71 | PNP (0.46) | TYMSPNPXDHALDH1A1 | |
| SCHEMBL28112184 | 0.71 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL15325124 | 0.69 | GDA (0.43) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3955746 | 0.68 | MGMT (0.44) | DHFRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2837630-B1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | ASYMCHEM LAB TIANJIN CO LTD (CN) | 2016-11-23 | — | — | EP | claimed |
| US-9371326-B2 | Method for synthesizing sapropterin dihydrochloride | ASYMCHEM LABORATORIES (TIANJIN) CO., LTD (CN) | 2016-06-21 | — | — | US | claimed |
| US-9365573-B2 | Method for synthesizing sapropterin dihydrochloride | ASYMCHEM LABORATORIES (TIANJIN) CO., LTD (CN) | 2016-06-14 | — | — | US | claimed |
| US-20150119573-A1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | TIANJIN ASYMCHEM PHARMACEUTICAL CO., LTD (CN) | 2015-04-30 | — | — | US | claimed |
| US-20150105555-A1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | TIANJIN ASYMCHEM PHARMACEUTICAL CO., LTD (CN) | 2015-04-16 | — | — | US | claimed |
| EP-2837629-A1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | Asymchem Laboratories (Tianjin) Co., Ltd (CN) | 2015-02-18 | — | — | EP | claimed |
| EP-2837630-A1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | Asymchem Laboratories (Tianjin) Co., Ltd (CN) | 2015-02-18 | — | — | EP | claimed |
| EP-1644384-B1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF ENTECAVIR | BRISTOL MYERS SQUIBB CO (US) | 2012-10-31 | — | — | EP | claimed |
| CN-102633799-A | Method for synthesizing sapropterin dihydrochloride from racemate intermediate separation route | ASYMCHEM LAB TIANJIN CO LTD | 2012-08-15 | — | — | CN | claimed |
| CN-102627644-A | Method for preparing sapropterin dihydrochloride through direct chiral synthesis method | ASYMCHEM LAB TIANJIN CO LTD | 2012-08-08 | — | — | CN | claimed |
| JP-4726491-B2 | — | — | 2011-07-20 | — | — | JP | claimed |
| CN-100379746-C | Process for the preparation of the antiviral agent [ 1S- (1 α,3 α,4 β) ] -2-amino-1, 9-dihydro-9- [ 4-hydroxy-3- (hydroxymethyl) -2-methylenecyclopentyl ] -6H-purin-6-one | BRISTOL MYERS SQUIBB CO (US) | 2008-04-09 | — | — | CN | claimed |
| US-20060106216-A1 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | PENDRI YADAGIRI R | 2006-05-18 | — | — | US | claimed |
| US-20060106215-A1 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | CHAN YEUNG Y | 2006-05-18 | — | — | US | claimed |
| EP-1644384-A2 | PROCESS AND INTERMEDIATES FOR SYNTHESIS ENTECAVIR | Bristol-Myers Squibb Company (US) | 2006-04-12 | — | — | EP | claimed |
| JP-2006509800-A | — | — | 2006-03-23 | — | — | JP | claimed |
| CN-1747959-A | Process for the preparation of the antiviral agent [ 1S- (1 α, 3 α, 4 β) ] -2-amino-1, 9-dihydro-9- [ 4-hydroxy-3- (hydroxymethyl) -2-methylenecyclopentyl ] -6H-purin-6-one | BRISTOL MYERS SQUIBB CO (US) | 2006-03-15 | — | — | CN | claimed |
| US-20040192912-A1 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-30 | — | — | US | claimed |
| WO-2004052310-A2 | PROCESS AND INTERMEDIATES FOR SYNTHESIS ENTECAVIR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-24 | — | — | WO | claimed |
| US-11912734-B2 | Solid-phase synthesis of oligonucleotides containing N6-(2-deoxy-alpha,beta-derythropentofuranosyl)-2,6-diamino-4-hydroxy-5-formamidopyrimidine (Fapy⋅dG) | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-02-27 | — | — | US | disclosed |
| US-11091509-B2 | HPPK inhibitors useful as antibacterial agents | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-08-17 | — | — | US | disclosed |
| US-20190241605-A1 | HPPK INHIBITORS USEFUL AS ANTIBACTERIAL AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2019-08-08 | — | — | US | disclosed |
| US-9993491-B2 | Guanine riboswitch binding compounds and their use as antibiotics | SOCPRA—SCIENCES ET GÉNIE S.E.C. (CA) | 2018-06-12 | — | — | US | disclosed |
| WO-2018071531-A1 | HPPK INHIBITORS USEFUL AS ANTIBACTERIAL AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-04-19 | — | — | WO | disclosed |
| EP-2837629-B1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | ASYMCHEM LABORATORIES (TIANJIN) CO LTD (CN) | 2017-03-22 | — | — | EP | disclosed |
| US-20160368944-A1 | LINKED PURINE PTERIN HPPK INHIBITORS USEFUL AS ANTIBACTERIAL AGENTS | US HEALTH (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160368944-A1 | LINKED PURINE PTERIN HPPK INHIBITORS USEFUL AS ANTIBACTERIAL AGENTS | US HEALTH (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160368944-A1 | LINKED PURINE PTERIN HPPK INHIBITORS USEFUL AS ANTIBACTERIAL AGENTS | US HEALTH (US) | 2016-12-22 | — | — | US | disclosed |
| EP-2837630-B1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | ASYMCHEM LAB TIANJIN CO LTD (CN) | 2016-11-23 | — | — | EP | disclosed |
| US-9453019-B2 | Linked purine pterin HPPK inhibitors useful as antibacterial agents | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-09-27 | — | — | US | disclosed |
| US-9453019-B2 | Linked purine pterin HPPK inhibitors useful as antibacterial agents | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-09-27 | — | — | US | disclosed |
| US-9453019-B2 | Linked purine pterin HPPK inhibitors useful as antibacterial agents | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-09-27 | — | — | US | disclosed |
| US-9371326-B2 | Method for synthesizing sapropterin dihydrochloride | ASYMCHEM LABORATORIES (TIANJIN) CO., LTD (CN) | 2016-06-21 | — | — | US | disclosed |
| US-9365573-B2 | Method for synthesizing sapropterin dihydrochloride | ASYMCHEM LABORATORIES (TIANJIN) CO., LTD (CN) | 2016-06-14 | — | — | US | disclosed |
| EP-2440533-B1 | GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS | SOCPRA SCIENCES ET GÉNIE S E C (CA) | 2015-09-23 | — | — | EP | disclosed |
| US-20150218167-A1 | LINKED PURINE PTERIN HPPK INHIBITORS USEFUL AS ANTIBACTERIAL AGENTS | US HEALTH (US) | 2015-08-06 | — | — | US | disclosed |
| US-20150218167-A1 | LINKED PURINE PTERIN HPPK INHIBITORS USEFUL AS ANTIBACTERIAL AGENTS | US HEALTH (US) | 2015-08-06 | — | — | US | disclosed |
| US-20150218167-A1 | LINKED PURINE PTERIN HPPK INHIBITORS USEFUL AS ANTIBACTERIAL AGENTS | US HEALTH (US) | 2015-08-06 | — | — | US | disclosed |
| CN-104788485-A | Process for preparing antiviral agent | BRISTOL MYERS SQUIBB CO | 2015-07-22 | — | — | CN | disclosed |
| US-20150150890-A1 | GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS | UNIVERSITE DE SHERBROOKE (CA) | 2015-06-04 | — | — | US | disclosed |
| US-20150150890-A1 | GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS | UNIVERSITE DE SHERBROOKE (CA) | 2015-06-04 | — | — | US | disclosed |
| US-9029344-B2 | Linked purine pterin HPPK inhibitors useful as antibacterial agents | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029344-B2 | Linked purine pterin HPPK inhibitors useful as antibacterial agents | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029344-B2 | Linked purine pterin HPPK inhibitors useful as antibacterial agents | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-05-12 | — | — | US | disclosed |
| CN-102675355-B | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL MYERS SQUIBB CO | 2015-05-06 | — | — | CN | disclosed |
| US-20150119573-A1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | TIANJIN ASYMCHEM PHARMACEUTICAL CO., LTD (CN) | 2015-04-30 | — | — | US | disclosed |
| US-20150105555-A1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | TIANJIN ASYMCHEM PHARMACEUTICAL CO., LTD (CN) | 2015-04-16 | — | — | US | disclosed |
| EP-2837629-A1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | Asymchem Laboratories (Tianjin) Co., Ltd (CN) | 2015-02-18 | — | — | EP | disclosed |
| EP-2837630-A1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | Asymchem Laboratories (Tianjin) Co., Ltd (CN) | 2015-02-18 | — | — | EP | disclosed |
| US-20130172285-A1 | LINKED PURINE PTERIN HPPK INHIBITORS USEFUL AS ANTIBACTERIAL AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2013-07-04 | — | — | US | disclosed |
| US-20130172285-A1 | LINKED PURINE PTERIN HPPK INHIBITORS USEFUL AS ANTIBACTERIAL AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2013-07-04 | — | — | US | disclosed |
| US-20130172285-A1 | LINKED PURINE PTERIN HPPK INHIBITORS USEFUL AS ANTIBACTERIAL AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2013-07-04 | — | — | US | disclosed |
| EP-2582712-A2 | LINKED PURINE PTERIN HPPK INHIBITORS USEFUL AS ANTIBACTERIAL AGENTS | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2013-04-24 | — | — | EP | disclosed |
| CN-101899063-B | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL MYERS SQUIBB CO | 2012-12-12 | — | — | CN | disclosed |
| EP-1644384-B1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF ENTECAVIR | BRISTOL MYERS SQUIBB CO (US) | 2012-10-31 | — | — | EP | disclosed |
| CN-102675355-A | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL MYERS SQUIBB CO | 2012-09-19 | — | — | CN | disclosed |
| CN-102633799-A | Method for synthesizing sapropterin dihydrochloride from racemate intermediate separation route | ASYMCHEM LAB TIANJIN CO LTD | 2012-08-15 | — | — | CN | disclosed |
| CN-102627644-A | Method for preparing sapropterin dihydrochloride through direct chiral synthesis method | ASYMCHEM LAB TIANJIN CO LTD | 2012-08-08 | — | — | CN | disclosed |
| US-20120122819-A1 | GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS | SOCPRA - SCIENCES ET GENIE S.E.C. (CA) | 2012-05-17 | — | — | US | disclosed |
| EP-2433941-A1 | Process for isolating the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | Bristol-Myers Squibb Company (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-2433941-A1 | Process for isolating the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | Bristol-Myers Squibb Company (US) | 2012-03-28 | — | — | EP | disclosed |
| WO-2011159471-A2 | LINKED PURINE PTERIN HPPK INHIBITORS USEFUL AS ANTIBACTERIAL AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011159471-A2 | LINKED PURINE PTERIN HPPK INHIBITORS USEFUL AS ANTIBACTERIAL AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-12-22 | — | — | WO | disclosed |
| CN-101130543-B | Process for preparing the antiviral agent [1s-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6h-purin-6-one | BRISTOL MYERS SQUIBB CO | 2011-06-08 | — | — | CN | disclosed |
| US-20110124634-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PONIARD PHARMACEUTICALS, INC. | 2011-05-26 | — | — | US | disclosed |
| US-20110124634-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PONIARD PHARMACEUTICALS, INC. | 2011-05-26 | — | — | US | disclosed |
| EP-2273882-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | Poniard Pharmaceuticals, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| CN-101899063-A | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL MYERS SQUIBB CO | 2010-12-01 | — | — | CN | disclosed |
| US-20100279974-A1 | Nucleosides With Non-Natural Bases as Anti-Viral Agents | IDENIX PHARMACEUTICALS, INC. | 2010-11-04 | — | — | US | disclosed |
| CN-101130552-B | Process for preparing the antiviral agent [1s-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6h-purin-6-one | BRISTOL MYERS SQUIBB CO | 2010-07-28 | — | — | CN | disclosed |
| WO-2009139834-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PONIARD PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | WO | disclosed |
| US-7550619-B2 | Intermediates in the preparation of the antiviral agent [1S-(1α, 3α, 4β)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxmethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550619-B2 | Intermediates in the preparation of the antiviral agent [1S-(1α, 3α, 4β)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxmethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550619-B2 | Intermediates in the preparation of the antiviral agent [1S-(1α, 3α, 4β)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxmethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-7541460-B2 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-3-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-02 | — | — | US | disclosed |
| US-7541460-B2 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-3-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-02 | — | — | US | disclosed |
| CN-100379746-C | Process for the preparation of the antiviral agent [ 1S- (1 α,3 α,4 β) ] -2-amino-1, 9-dihydro-9- [ 4-hydroxy-3- (hydroxymethyl) -2-methylenecyclopentyl ] -6H-purin-6-one | BRISTOL MYERS SQUIBB CO (US) | 2008-04-09 | — | — | CN | disclosed |
| CN-101130543-A | Process for preparing the antiviral agent [1s-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6h-purin-6-one | BRISTOL MYERS SQUIBB CO (US) | 2008-02-27 | — | — | CN | disclosed |
| CN-101130552-A | Process for preparing the antiviral agent [1s-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6h-purin-6-one | BRISTOL MYERS SQUIBB CO (US) | 2008-02-27 | — | — | CN | disclosed |
| US-20060106216-A1 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | PENDRI YADAGIRI R | 2006-05-18 | — | — | US | disclosed |
| US-20060106215-A1 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | CHAN YEUNG Y | 2006-05-18 | — | — | US | disclosed |
| US-7034152-B2 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta )]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-25 | — | — | US | disclosed |
| EP-1644384-A2 | PROCESS AND INTERMEDIATES FOR SYNTHESIS ENTECAVIR | Bristol-Myers Squibb Company (US) | 2006-04-12 | — | — | EP | disclosed |
| CN-1747959-A | Process for the preparation of the antiviral agent [ 1S- (1 α, 3 α, 4 β) ] -2-amino-1, 9-dihydro-9- [ 4-hydroxy-3- (hydroxymethyl) -2-methylenecyclopentyl ] -6H-purin-6-one | BRISTOL MYERS SQUIBB CO (US) | 2006-03-15 | — | — | CN | disclosed |
| US-20040192912-A1 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-30 | — | — | US | disclosed |
| WO-2004052310-A2 | PROCESS AND INTERMEDIATES FOR SYNTHESIS ENTECAVIR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
| CN-1438890-A | Adenosine receptor modulators | HOFFMANNLA ROCHE AG F (CH) | 2003-08-27 | — | — | CN | disclosed |
| US-6586441-B2 | 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders | HOFFMAN-LA ROCHE INC. | 2003-07-01 | — | — | US | disclosed |
| EP-1261327-A2 | ADENOSINE RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2002-12-04 | — | — | EP | disclosed |
| US-20010027196-A1 | Adenosine receptor ligands and their use in the treatment of disease | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-04 | — | — | US | disclosed |
| WO-2001062233-A2 | ADENOSINE RECEPTOR MODULATORS | F. HOFFMANN LA ROCHE AG (CH) | 2001-08-30 | — | — | WO | disclosed |
| EP-0434450-B1 | Therapeutic nucleosides | WELLCOME FOUND (GB) | 1999-07-07 | — | — | EP | disclosed |
| EP-0921121-A1 | Intermediates to therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1999-06-09 | — | — | EP | disclosed |
| EP-0921114-A1 | Intermediates to therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1999-06-09 | — | — | EP | disclosed |
| EP-0784624-A1 | PURINE AND GUANINE COMPOUNDS AS INHIBITORS OF PNP | Chiroscience Limited (GB) | 1997-07-23 | — | — | EP | disclosed |
| WO-1996011200-A1 | PURINE AND GUANINE COMPOUNDS AS INHIBITORS OF PNP | CHIROSCIENCE LIMITED (GB) | 1996-04-18 | — | — | WO | disclosed |
| EP-0631581-A4 | INTERMEDIATES AND A PROCESS FOR SYNTHESIS OF TETRAHYDROPTERIDINE C6-STEREOISOMERS, INCLUDING (6S)-TETRAHYDROFOLATE AND N5-FORMYL-(6S)-TETRHYDROFOLATE. | BAILEY STEVENW (US) | 1995-08-02 | — | — | EP | disclosed |
| EP-0631581-A1 | INTERMEDIATES AND A PROCESS FOR SYNTHESIS OF TETRAHYDROPTERIDINE C6-STEREOISOMERS, INCLUDING (6S)-TETRAHYDROFOLATE AND N5-FORMYL-(6S)-TETRHYDROFOLATE | BAILEY, StevenW. (US) | 1995-01-04 | — | — | EP | disclosed |
| US-5350851-A | Intermediates and a process for synthesis of tetrahydropteridine C6-stereoisomers, including (6S)-tetrahydrofolate and N5-formyl-(6S)-tetrahydrofolate | SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION (US) | 1994-09-27 | — | — | US | disclosed |
| WO-1993019069-A1 | INTERMEDIATES AND A PROCESS FOR SYNTHESIS OF TETRAHYDROPTERIDINE C6-STEREOISOMERS, INCLUDING (6S)-TETRAHYDROFOLATE AND N5-FORMYL-(6S)-TETRHYDROFOLATE | BAILEY STEVEN W (US) | 1993-09-30 | — | — | WO | disclosed |
| US-5206435-A | Viricides; HIV, aides | BURROUGHS WELLCOME CO. (US) | 1993-04-27 | — | — | US | disclosed |
| US-5198547-A | Process for N5-formylating tetrahydropteridines | SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION, USA (US) | 1993-03-30 | — | — | US | disclosed |
| EP-0481320-A1 | Novel cyclobutane derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1992-04-22 | — | — | EP | disclosed |
| US-5102879-A | Cytotoxic to t-cells | WARNER-LAMBERT COMPANY (US) | 1992-04-07 | — | — | US | disclosed |
| US-5101030-A | Used in treatment of autoimmune diseases, gout, psoriasis or transplant rejection | WARNER-LAMBERT COMPANY (US) | 1992-03-31 | — | — | US | disclosed |
| US-5087697-A | Aids, viricides | BURROUGHS WELLCOME CO. (US) | 1992-02-11 | — | — | US | disclosed |
| US-5061707-A | Treats autoimmune diseases, gout, or transplantation rejection | WARNER-LAMBERT COMPANY (US) | 1991-10-29 | — | — | US | disclosed |
| EP-0260491-B1 | 9-DEAZAGUANINES | WARNER LAMBERT CO (US) | 1991-09-11 | — | — | EP | disclosed |
| EP-0434450-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-06-26 | — | — | EP | disclosed |
| US-4988702-A | Treatment of autoimmune disease or rejection of transplanted organs | WARNER-LAMBERT COMPANY (US) | 1991-01-29 | — | — | US | disclosed |
| EP-0393499-A1 | Process for preparing carbovir and new intermediate products therefor | F. HOFFMANN-LA ROCHE AG (CH) | 1990-10-24 | — | — | EP | disclosed |
| EP-0383239-A1 | Isomeric dideoxynucleosides, their preparation and their use in medicaments | F. HOFFMANN-LA ROCHE AG (CH) | 1990-08-22 | — | — | EP | disclosed |
| US-4939252-A | Novel intermediates for the preparation of Carbovir | HOFFMANN-LA ROCHE INC. (US) | 1990-07-03 | — | — | US | disclosed |
| US-4923872-A | AUTOIMMUNE DISEASES, GOUT, PSORIASIS; BIOCOMPATIBILITY | WARNER-LAMBERT CO. (US) | 1990-05-08 | — | — | US | disclosed |
| EP-0108890-B1 | PHARMACEUTICALLY ACTIVE PTERIDINE DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-12-07 | — | — | EP | disclosed |
| EP-0260491-A1 | 9-deazaguanines | WARNER-LAMBERT COMPANY (US) | 1988-03-23 | — | — | EP | disclosed |
| EP-0108890-A2 | Pharmaceutically active pteridine derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-05-23 | — | — | EP | disclosed |
| EP-0108890-A2 | Pharmaceutically active pteridine derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368944-A1 | LINKED PURINE PTERIN HPPK INHIBITORS USEFUL AS ANTIBACTERIAL AGENTS | PDXK, HPRT1, PLPBP | TYMS 67/4885GRIN2D 4100/4885GRIN3B 3532/4885 |
| US-20040192912-A1 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | SAMHD1, NUDT1, ENTPD1 | TYMS 52/4885GRIN2D 1335/4885GRIN3B 539/4885 |
| US-20130172285-A1 | LINKED PURINE PTERIN HPPK INHIBITORS USEFUL AS ANTIBACTERIAL AGENTS | PDXK, HPRT1, PLPBP | TYMS 57/4885GRIN2D 4074/4885GRIN3B 3575/4885 |
| US-20060106216-A1 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | SAMHD1, NUDT1, ENTPD1 | TYMS 42/4885GRIN2D 1413/4885GRIN3B 608/4885 |
| US-20010027196-A1 | Adenosine receptor ligands and their use in the treatment of disease | ADORA2A, ADORA2B, ADORA1 | TYMS 2570/4885GRIN2D 251/4885GRIN3B 254/4885 |
| US-20150150890-A1 | GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS | GDA, RNMT, GNPDA1 | TYMS 1685/4885GRIN2D 3706/4885GRIN3B 1275/4885 |
| US-20190241605-A1 | HPPK INHIBITORS USEFUL AS ANTIBACTERIAL AGENTS | PDXK, PHKG1, DTYMK | TYMS 74/4885GRIN2D 4159/4885GRIN3B 3288/4885 |
| US-20150105555-A1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | CYP51A1, DHCR7, LSS | TYMS 1561/4885GRIN2D 3792/4885GRIN3B 2805/4885 |
| US-20110124634-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PARK7, BDNF, BACE1 | TYMS 1697/4885GRIN2D 4098/4885GRIN3B 1363/4885 |
| US-20100279974-A1 | Nucleosides With Non-Natural Bases as Anti-Viral Agents | PNP, NSUN2, NME2 | TYMS 148/4885GRIN2D 3951/4885GRIN3B 2261/4885 |
| US-20150218167-A1 | LINKED PURINE PTERIN HPPK INHIBITORS USEFUL AS ANTIBACTERIAL AGENTS | PDXK, HPRT1, PLPBP | TYMS 57/4885GRIN2D 4074/4885GRIN3B 3575/4885 |
| US-20150119573-A1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | DHCR7, CYP51A1, HMGCR | TYMS 3404/4885GRIN2D 3682/4885GRIN3B 2184/4885 |
| US-11091509-B2 | HPPK inhibitors useful as antibacterial agents | PDXK, PHKG1, DTYMK | TYMS 74/4885GRIN2D 4159/4885GRIN3B 3288/4885 |
| US-20120122819-A1 | GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS | GDA, RNMT, GNPDA1 | TYMS 1685/4885GRIN2D 3706/4885GRIN3B 1275/4885 |
| US-20060106215-A1 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | SAMHD1, NUDT1, ENTPD1 | TYMS 42/4885GRIN2D 1413/4885GRIN3B 608/4885 |
| US-11912734-B2 | Solid-phase synthesis of oligonucleotides containing N6-(2-deoxy-alpha,beta-derythropentofuranosyl)-2,6-diamino-4-hydroxy-5-formamidopyrimidine (Fapy⋅dG) | DPYD, TYMP, RNGTT | TYMS 9/4885GRIN2D 3211/4885GRIN3B 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.